


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) ~~Compounds of the A compound of~~ formula I:



in which:

~~n is an integer chosen from 1, 2 and 3~~ 1;

Y represents O; N-OR<sup>9</sup>, in which R<sup>9</sup> represents H or a saturated hydrocarbon-based aliphatic group; CR<sup>10</sup>R<sup>11</sup>, in which R<sup>10</sup> and R<sup>11</sup>, which may be identical or different, represent H or a saturated hydrocarbon-based aliphatic group;

R<sup>1</sup> and R<sup>2</sup>, which may be identical or different, represent H or a saturated aliphatic hydrocarbon-based chain; or alternatively R<sup>1</sup> and R<sup>2</sup> together form an optionally substituted saturated aliphatic hydrocarbon-based chain;

~~the radicals~~ R<sup>3</sup> and R<sup>4</sup>, which may be identical or different, take any of the meanings given above for R<sup>1</sup> and R<sup>2</sup>, or alternatively

R<sup>1</sup> and ~~the group~~ R<sup>4</sup> borne by the carbon alpha to CR<sup>1</sup>R<sup>2</sup> represent nothing and a double bond links the CR<sup>1</sup>R<sup>2</sup> carbon to the alpha CR<sup>3</sup>R<sup>4</sup> carbon; or alternatively

one of ~~the radicals~~ R<sup>1</sup> and R<sup>2</sup> forms with one of ~~the radicals~~ R<sup>3</sup> and R<sup>4</sup> an optionally substituted saturated or unsaturated aliphatic hydrocarbon-based chain;

one of ~~the radicals~~ R<sup>5</sup> and R<sup>6</sup> represents W, and the other represents Z<sub>1</sub>, which is ~~chosen from~~ a saturated or unsaturated aliphatic hydrocarbon-based radical; an optionally substituted, saturated, unsaturated and/or aromatic carbocyclic or heterocyclic radical; a radical -alk-Cy, in which alk represents an alkylene chain and Cy represents an optionally substituted saturated, unsaturated and/or aromatic heterocyclic or carbocyclic radical;

W represents -XL-CO<sub>2</sub>R<sup>7</sup>; ~~X-L-Tet, in which X and L are as defined below and Tet represents optionally substituted tetrazole; in which~~

L represents a saturated or unsaturated aliphatic hydrocarbon-based chain, which is optionally substituted and/or optionally interrupted by optionally substituted arylene;

X represents O; NR<sup>8</sup>, in which R<sup>8</sup> represents H; a saturated aliphatic hydrocarbon-based group; a group -CO-R' or -SO<sub>2</sub>-R', in which R' takes any of the meanings given below for R<sup>7</sup> with the exception of H; or R<sup>8</sup> represents an optionally substituted aromatic carbocyclic group; or X represents S(O)<sub>m</sub>, in which m is ~~chosen from 0, 1 and 2~~ 0, 1 or 2;

R<sup>7</sup> represents H; a saturated or unsaturated aliphatic hydrocarbon-based group; an optionally substituted, saturated, unsaturated and/or aromatic carbocyclic group; an optionally substituted, saturated, unsaturated and/or aromatic heterocyclic group; ~~and the or a pharmaceutically acceptable derivatives, salts, solvates and stereoisomers thereof, and also mixtures thereof in all proportions~~ salt, or solvate thereof.

2. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~characterized in that wherein~~ R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are independently ~~chosen from~~ a hydrogen atom ~~and~~ or alkyl.


3. (Cancelled)

4. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~characterised in that wherein~~ R<sup>7</sup> represents H or alkyl.

5. (Cancelled)


6. (Currently Amended) ~~Compound~~ A compound according to Claim 1, ~~characterised in that wherein~~ L represents alkylene, alkenylene or -alk<sup>o</sup>-Ar<sup>o</sup>, in which alk<sup>o</sup> represents alkylene and Ar<sup>o</sup> represents optionally substituted phenylene.

7. (Currently Amended) ~~Compounds~~ A compound according to Claim 6, ~~characterised in that wherein~~ L represents



8. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~characterised in that wherein~~ Z represents alkyl optionally substituted by one or more radicals T; alkenyl optionally substituted by one or more radicals T; alkynyl optionally substituted by one or more radicals T; phenyl optionally substituted by one or more radicals T; cycloalkyl optionally substituted by one or more radicals T; monocyclic or bicyclic heteroaryl optionally substituted by one or more radicals T; -alk<sup>1</sup>-Cy<sup>1</sup>, in which alk<sup>1</sup> represents alkylene, preferably CH<sub>2</sub> and Cy<sup>1</sup> represents phenyl optionally substituted by one or more radicals T, or alternatively Cy<sup>1</sup> represents cycloalkyl, optionally substituted by one or more radicals T; T ~~being chosen from~~ is an optionally halogenated alkyl; optionally halogenated alkoxy; a halogen atom; and or cyano.

9. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~characterised in that n=1; wherein~~ R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> represent a hydrogen atom; Y represents O; R<sup>5</sup> represents (C<sub>1</sub>-C<sub>10</sub>)alkyl; (C<sub>2</sub>-C<sub>10</sub>)alkynyl; -alk<sup>1</sup>-Cy<sup>1</sup>, in which alk<sup>1</sup> represents (C<sub>1</sub>-C<sub>3</sub>)alkylene and Cy<sup>1</sup> represents phenyl optionally substituted by one or more radicals T, in which T is an optionally halogenated alkyl; optionally halogenated alkoxy; a halogen atom; or cyano



; R<sup>6</sup> represents W, in which X represents O or NH; and L represents (C<sub>1</sub>-C<sub>3</sub>)alkylene.









10. (Currently Amended) ~~Compounds~~ A compound according to Claim 8, ~~characterised in that wherein~~ X represents NH; and R<sup>5</sup> represents (C<sub>1</sub>-C<sub>10</sub>)alkyl.

11. (Currently Amended) ~~Compounds~~ A compound according to Claim 8, ~~characterised in that wherein~~ X represents O; and R<sup>5</sup> represents (C<sub>1</sub>-C<sub>10</sub>)alkyl; (C<sub>2</sub>-C<sub>10</sub>)alkynyl; and or -alk<sup>1</sup>-Cy<sup>1</sup>, in which alk<sup>1</sup> represents (C<sub>1</sub>-C<sub>3</sub>)alkylene and Cy<sup>1</sup> represents phenyl.

12. (Currently Amended) ~~Compounds~~ A compound according to Claim 8, ~~characterised in that wherein~~ Z represents alkyl, optionally substituted by cyano; phenyl, optionally substituted by trifluoromethyl, with halogen, with alkyl or with alkoxy; phenylalkyl, in

which phenyl is substituted by one or more halogen atoms, alkyl or alkoxy; alkynyl; or cycloalkylalkyl.

13. (Currently Amended) Compounds A a compound according to Claim 1, ~~chosen from which is one of the following compounds~~



~~and the or a pharmaceutically acceptable derivatives, salts, solvates and stereoisomers thereof, and also mixtures thereof in all proportions salt, or solvate thereof.~~

14. (Currently Amended) Pharmaceutical A a pharmaceutical composition comprising an ~~effective amount of at least one compound chosen from the compounds of the~~ a compound of formula I according to Claim 1 ~~and/or the pharmaceutically acceptable~~


derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all proportions, in combination with at least one and a pharmaceutically acceptable vehicle.

15. (Cancelled)

16. (Currently Amended) ~~Use of a compound of the formula I according to Claim 1 and/or the pharmaceutically acceptable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all proportions, for the preparation of a medicament~~ A method for the treatment of an individual suffering from a disease or condition mediated by an insufficiency of activity of the PPAR $\alpha$  and PPAR $\gamma$  isoforms in their role of regulating lipidaemia and glycaemia comprising administering to said individual an effective amount of a pharmaceutical composition according to claim 14.

17. (Currently Amended) ~~Use, according to Claim 16, of compounds of the formula I and/or the physiologically acceptable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all proportions, for the preparation of a medicament for the prevention of or~~ A method for treating dyslipidaemia, atherosclerosis and or diabetes comprising administering a subject in need thereof an effective amount of a pharmaceutical composition according to claim 14.


18. (Currently Amended) ~~Process for the preparation of a compound of the~~ A process for preparing a compound of formula I according to Claim 1, characterised in that comprising reacting a compound of the formula II:



in which


R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, n and Y are as defined above for formula I, G represents -XH, in which X is S or O, NHCOF<sub>3</sub> or NHR<sup>8</sup>, R<sup>8</sup> being as defined for formula I ~~in Claim 1~~; and Z° is a radical

that is a precursor of Z, or alternatively Z<sup>o</sup> represents Z, Z being as defined for formula I in Claim 1, Z<sup>o</sup> and G being in positions 2 and 3 of the phenyl nucleus;  
is reacted with a compound of the formula III:



in which R<sup>7</sup> and L are as defined in Claim 1 for formula I and Gp represents a leaving group, in the presence of a base.

19. (Currently Amended) ~~Process for the preparation of a compound of the~~  
A process for preparing a compound of formula I according to Claim 1, in which Z represents  
Cy, in which Cy denotes an optionally substituted aryl or heteroaryl group, ~~characterised in~~  
~~that it comprises the reaction of a compound of the~~  
comprising reacting a compound of formula IVa:




in which D represents -NHCOCF<sub>3</sub> or -X-L-CO<sub>2</sub>R<sup>7</sup>, and L, R<sup>7</sup>, Y, X, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and n are as defined for formula I in Claim 1, and Hal represents a halogen atom, preferably a bromine or iodine atom, the groups -Hal and D being in position 2 or 3, with an arylboronic or heteroarylboronic acid of the formula V:



in which the group Cy optionally bears one or more substituents, in the presence of a palladium 0 complex and a mineral or organic base.


20. (Currently Amended) ~~Process for the preparation of a compound of the~~  
A process for preparing a compound of formula I according to Claim 1, in which Z represents -  
CH<sub>2</sub>-π, in which π represents alkyl; alkenyl; alkynyl; Cy<sup>1</sup>, wherein Cy<sup>1</sup> being is as defined for Cy

in Claim 1 for formula I; or  $-\text{alk}^2-\text{Cy}^1$ , wherein  $\text{alk}^2$  representing represents alkylene and  $\text{Cy}^1$  being is as defined above, the said process being characterised in that comprising reacting a compound of the formula IVa:



in which  $R^1, R^2, R^3, R^4, n, Y, X, L, R^7$  and  $D$  are as defined in Claim 18

in which  $D$  represents  $-\text{NHCOCF}_3$  or  $-\text{X-L-CO}_2\text{R}^7$ , and  $L, R^7, Y, X, R^1, R^2, R^3, R^4$  and  $n$  are as defined for formula I, and  $\text{Hal}$  represents a halogen atom, preferably an iodine or bromine atom,  $-\text{Hal}$  and  $D$  being in position 2 or 3, is reacted with a compound of the formula VII




in which  $\pi$  is as defined above,

in the presence of a palladium complex, such as bis(triphenylphosphine)dichloropalladium.

21. (Currently Amended) Process for the preparation of a compound of the A process for preparing a compound of formula I according to Claim 1 in which  $Y$  represents  $\text{N-OH}$ , characterised in that it comprises the reaction of the corresponding compound of the comprising reacting a compound of formula I in which  $Y = \text{O}$  with a hydroxylamine salt in the presence of an alkali metal salt.


22. (Currently Amended) Process for the preparation of a compound of the A process for preparing a compound of formula I in which  $Y$  represents  $\text{CR}^{10}\text{R}^{11}$ , in which  $\text{R}^{10}$  and  $\text{R}^{11}$  are as defined in Claim 1, characterised in that the corresponding compound of the for formula I, comprising reacting a compound of formula I in which  $Y$  represents  $\text{O}$  is reacted with a compound of the formula IX



in the presence of a base.

23 - 30. (Cancelled)

31. (New) A compound of formula I:



in which:

n is 1;

Y represents O; N-OR<sup>9</sup>, in which R<sup>9</sup> represents H or a saturated hydrocarbon-based aliphatic group; CR<sup>10</sup>R<sup>11</sup>, in which R<sup>10</sup> and R<sup>11</sup>, which may be identical or different, represent H or a saturated hydrocarbon-based aliphatic group;

R<sup>1</sup> and R<sup>2</sup>, which may be identical or different, represent H or a saturated aliphatic hydrocarbon-based chain; or alternatively R<sup>1</sup> and R<sup>2</sup> together form an optionally substituted saturated aliphatic hydrocarbon-based chain;

R<sup>3</sup> and R<sup>4</sup>, which may be identical or different, take any of the meanings given above for R<sup>1</sup> and R<sup>2</sup>, or alternatively

R<sup>1</sup> and R<sup>4</sup> borne by the carbon alpha to CR<sup>1</sup>R<sup>2</sup> represent nothing and a double bond links the CR<sup>1</sup>R<sup>2</sup> carbon to the alpha CR<sup>3</sup>R<sup>4</sup> carbon; or alternatively

one of R<sup>1</sup> and R<sup>2</sup> forms with one of R<sup>3</sup> and R<sup>4</sup> an optionally substituted saturated or unsaturated aliphatic hydrocarbon-based chain;

one of R<sup>5</sup> and R<sup>6</sup> represents W, and the other represents Z, which is a saturated or unsaturated aliphatic hydrocarbon-based radical; an optionally substituted, saturated, unsaturated and/or aromatic carbocyclic or heterocyclic radical; a radical -alk-Cy, in which alk represents an alkylene chain and Cy represents an optionally substituted saturated, unsaturated and/or aromatic heterocyclic or carbocyclic radical;

W represents -XL-CO<sub>2</sub>R<sup>7</sup>;









L represents a saturated or unsaturated aliphatic hydrocarbon-based chain, which is optionally

substituted and/or optionally interrupted by optionally substituted arylene;

X represents O; NR<sup>8</sup>, in which R<sup>8</sup> represents H; a saturated aliphatic hydrocarbon-based group; a group -CO-R' or -SO<sub>2</sub>-R', in which R' takes any of the meanings given below for R<sup>7</sup> with the exception of H; or R<sup>8</sup> represents an optionally substituted aromatic carbocyclic group; or X represents S(O)<sub>m</sub>, in which m is 0, 1 or 2;

R<sup>7</sup> represents H; a saturated or unsaturated aliphatic hydrocarbon-based group; an optionally substituted, saturated, unsaturated and/or aromatic carbocyclic group; an optionally substituted, saturated, unsaturated and/or aromatic heterocyclic group; or a pharmaceutically acceptable salt thereof.

32. (New) A compound according to Claim 31, which is one of the following compounds



or a pharmaceutically acceptable salt thereof.

33. (New) A composition comprising stereoisomers of a compound according to Claim 31.

34. (New) A composition comprising a mixture of isomers of a compound according to Claim 31.

35. (New) A composition comprising stereoisomers of a compound according to Claim 32.

36. (New) A composition comprising a mixture of isomers of a compound according to Claim 32.

37. (New) A pharmaceutical composition comprising a compound of formula I according to Claim 31 and a pharmaceutically acceptable vehicle.

38. (New) A method for the treatment of an individual suffering from a disease or condition mediated by an insufficiency of activity of the PPAR $\alpha$  and PPAR $\gamma$  isoforms in their role of regulating lipidaemia and glycaemia comprising administering to said individual an effective amount of a pharmaceutical composition according to claim 37.

39. (New) A method for treating dyslipidaemia, atherosclerosis or diabetes comprising administering a subject in need thereof an effective amount of a pharmaceutical composition according to claim 37.

40. (New) A pharmaceutical composition comprising a compound of formula I according to Claim 32 and a pharmaceutically acceptable vehicle.